Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Critical comments on galactosyltransferase.

A L Pohl

    Cancer Detection and Prevention
    |January 1, 1984
    PubMed
    Summary

    Galactosyltransferase II (GT II) shows puzzling heterogeneity and a complex relationship with serum glycoproteins, limiting its use as a cancer marker. Current assays are too complex for routine clinical cancer diagnosis.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A comparative study of autistic and non-autistic women's experience of motherhood.

    Molecular autism·2020
    Same author

    Evaluation of laboratory data by conventional statistics and by three types of neural networks.

    Clinical chemistry·1993
    Same author

    Detection of monoclonal gammopathies in serum electrophoresis by neural networks.

    Clinical chemistry·1993
    Same author

    A new ADP-ribosyltransferase in human serum: significance in cancer.

    The International journal of biological markers·1987
    Same author

    Enzyme activities in human breast tumor cells and sera.

    Cancer detection and prevention·1985
    Same author

    Present value of tumor markers in the clinic.

    Cancer detection and prevention·1983

    Area of Science:

    • Biochemistry
    • Oncology
    • Clinical Chemistry

    Background:

    • Galactosyltransferase (GT) has been investigated as a potential biomarker for various malignancies.
    • Specific variants like GT II were explored for improved tumor detection in cancer diagnostics.

    Purpose of the Study:

    • To characterize the tumor-associated GT II variant for enhanced clinical applicability in cancer testing.
    • To investigate the relationship between serum GT forms and serum glycoproteins in the context of malignancy.

    Main Methods:

    • Analytical and preparative characterization of GT II.
    • Investigation of serum-GT forms and their adducts with serum glycoproteins.
    • Evaluation of the reproducibility and practicality of GT II assays.

    Main Results:

    • Attempts to characterize GT II revealed significant heterogeneity rather than improved specificity for cancer.
    • A complex relationship was observed between serum-GT forms and acceptorlike serum glycoproteins, suggesting a general host response.
    • The GT II assay was found to be laborious, time-consuming, and not readily reproducible.

    Conclusions:

    • The heterogeneity and complex interactions of GT forms challenge its utility as a specific cancer biomarker.
    • Current GT II assays are not suitable for routine clinical cancer diagnosis due to technical limitations.
    • The GT assay is primarily of research interest and not yet applicable for patient care in cancer diagnostics.

    Related Experiment Videos